Chemotherapy (Parasitic): Anti‑amoebic Drugs and Anthelmintics

Introduction / Overview

Parasitic infections remain a significant burden in many parts of the world, affecting millions of individuals annually. Among these, amoebic dysentery caused by Entamoeba histolytica and helminthic diseases such as ascariasis, trichuriasis, and onchocerciasis are prevalent. The primary therapeutic strategy for these infections involves the administration of chemotherapeutic agents that target specific biological pathways of the parasites while sparing host tissues. This chapter aims to equip medical and pharmacy students with an in‑depth understanding of anti‑amoebic and anthelmintic agents, encompassing their pharmacodynamics, pharmacokinetics, clinical applications, safety profiles, and considerations for special populations.

• Identify the principal classes of anti‑amoebic and anthelmintic drugs and their chemical classification.
• Describe the molecular mechanisms by which these agents exert antiparasitic activity.
• Explain key pharmacokinetic parameters relevant to dosing regimens.
• Recognize therapeutic indications, common adverse effects, and major drug interactions.
• Understand special considerations for use in pregnancy, lactation, pediatrics, geriatrics, and patients with organ dysfunction.

Classification

Anti‑amoebic Agents

• Metronidazole & Tinidazole – Nitroimidazole derivatives.
• Iodoquinol – Iodinated benzoquinol.
• Paromomycin – Aminoglycoside antibiotic.
• Nitazoxanide – Thiazol-2-yl‑pyrimidine derivative.

Anthelmintic Agents

• Benzimidazoles (Albendazole, Mebendazole) – Microtubule inhibitors.
• Ivermectin – Macrocyclic lactone.
• Pyrantel Pamoate – Neurotoxin analog.
• Pyrimethamine & Sulfadiazine – Antifolate combination.
• Praziquantel – S‑piperidone derivative.

Chemical Classification Highlights

Many anti‑amoebic agents share a structural motif that facilitates the reduction of nitro groups under anaerobic conditions, whereas anthelmintics often contain heterocyclic rings or lactone structures that interact with parasite-specific proteins. These chemical features underpin the pharmacodynamic properties discussed subsequently.

Mechanism of Action

Anti‑amoebic Drugs

Metronidazole & Tinidazole are prodrugs that undergo intracellular reduction by parasite ferredoxin and other reductases. The resulting nitro‑radicals generate DNA strand breaks and inhibit key metabolic enzymes, ultimately leading to parasite cell death. The selectivity arises because human cells possess lower reductase activity under anaerobic conditions.

Iodoquinol accumulates within the parasite’s cytosol and interferes with the electron transport chain, generating reactive oxygen species that damage cellular proteins. Its mechanism also involves inhibition of parasite DNA synthesis by intercalating into nucleic acids.

Paromomycin binds to the 30S ribosomal subunit of the parasite, disrupting protein synthesis. This action is selective because the parasite’s ribosomes differ in conformation from the mammalian counterpart.

Nitazoxanide is converted to its active metabolite, tizoxanide, which disrupts parasite energy metabolism by inhibiting pyruvate:ferredoxin oxidoreductase, a critical enzyme in anaerobic glycolysis.

Anthelmintic Drugs

Albendazole & Mebendazole bind to β‑tubulin of helminth microtubules, preventing polymerization. The resulting depolymerization impairs glucose uptake, leading to energy depletion and parasite paralysis. These agents are highly effective against nematodes and cestodes.

Ivermectin binds to glutamate‑gated chloride channels in parasite nerve and muscle cells, increasing chloride ion permeability. The hyperpolarization of nerve and muscle membranes causes flaccid paralysis and expulsion of the parasite.

Pyrantel Pamoate acts as a nicotinic acetylcholine receptor agonist, causing sustained depolarization of the parasite’s neuromuscular system. This leads to spastic paralysis and subsequent expulsion.

Pyrimethamine & Sulfadiazine inhibit 5‑hydroxy‑4‑methyl‑pyrimidine‑5‑phosphate (DHFR) and dihydropteroate synthase, respectively, impairing folate synthesis in the parasite. The antifolate combination is effective against protozoan parasites such as Toxoplasma gondii.

Praziquantel induces rapid calcium influx into parasite muscle cells, precipitating spasms and tegumental rupture. The disruption of the parasite’s outer layer facilitates immune-mediated clearance.

Pharmacokinetics

Anti‑amoebic Agents

Metronidazole is well absorbed orally with an absolute bioavailability of ≈ 100 %. Peak plasma concentrations (C_max) are reached within 30–60 min (t_max). The drug undergoes hepatic N‑acetylation and glucuronidation, with a half‑life (t_1/2) of 8 h. Renal excretion accounts for ≈ 30 % of total clearance. Dosage adjustments are generally unnecessary in mild to moderate hepatic impairment; however, in severe hepatic dysfunction, dose reduction may be warranted due to prolonged t_1/2. Renal impairment has minimal impact, but caution is advised in patients requiring high doses.

Tinidazole displays similar absorption kinetics but possesses a longer t_1/2 of 12–14 h, allowing once‑daily dosing. Its metabolism is primarily hepatic, with a smaller contribution from renal excretion. In patients with renal insufficiency, no dose adjustment is typically required, while mild hepatic impairment may necessitate a 25 % reduction.

Iodoquinol achieves peak plasma levels within 1–2 h. The drug has a t_1/2 of approximately 24 h, with hepatic metabolism via oxidation and conjugation. Renal excretion is the main elimination pathway; therefore, dose reduction may be considered in severe renal impairment.

Paromomycin is poorly absorbed from the gastrointestinal tract (< 10 %). Consequently, it achieves high luminal concentrations while systemic exposure remains negligible, reducing systemic toxicity. The drug is excreted unchanged by the kidneys, with a t_1/2 of 2–4 h. Dose adjustment is not routinely required in renal impairment.

Nitazoxanide is rapidly hydrolyzed to tizoxanide, which exhibits an oral bioavailability of 20–30 %. Peak concentrations are reached in 1–2 h, with a t_1/2 of 6–10 h. Metabolism occurs via glucuronidation; renal excretion accounts for 50–60 % of clearance. No significant dose adjustment is needed for mild to moderate hepatic or renal dysfunction.

Anthelmintic Agents

Albendazole is absorbed in the small intestine; however, absorption is highly variable and can be enhanced by concomitant fatty meals (C_max increases by ≈ 1.5–2 fold). The drug is rapidly converted to albendazole sulfoxide, its active metabolite, which has a t_1/2 of 1–2 h. Hepatic metabolism via CYP3A4 predominates; renal excretion is minimal. In hepatic insufficiency, the active metabolite accumulates, necessitating dose reduction. Renal impairment has negligible impact on pharmacokinetics.

Mebendazole demonstrates poor systemic absorption (< 1 %) and is primarily excreted unchanged in feces. Consequently, it is effective against intestinal parasites but limited against systemic infections. The drug’s t_1/2 is short (< 1 h) due to rapid biliary excretion. Dose adjustment is not required for hepatic or renal disease.

Ivermectin is highly lipophilic and poorly soluble, leading to a t_max of 4–6 h. The drug is extensively metabolized by hepatic CYP3A4, with a t_1/2 of 12–36 h. Renal excretion accounts for < 10 % of clearance. Severe hepatic impairment may necessitate dose reduction; renal dysfunction has minimal effect.

Pyrantel Pamoate is poorly absorbed (< 5 %) and is mainly excreted via bile. The drug’s t_1/2 is 1–2 h. No dose adjustment is required for hepatic or renal impairment.

Pyrimethamine is well absorbed orally; hepatic metabolism via CYP2C9 and CYP2C19 yields an active metabolite. The t_1/2 is 2–3 days. Renal excretion is the major route; dose reduction is recommended in severe renal impairment. Hepatic dysfunction may prolong t_1/2, warranting dose adjustment.

Sulfadiazine is absorbed with a C_max achieved in 1–2 h. The drug undergoes hepatic conjugation and renal excretion. The t_1/2 is 8–12 h. Dose adjustment is advised in renal insufficiency but not typically required for hepatic impairment.

Praziquantel demonstrates rapid absorption; peak plasma concentrations are reached within 1–2 h. The drug is metabolized by CYP3A4 and CYP2C19, with a t_1/2 of 2–4 h. Renal excretion accounts for < 25 % of clearance. In hepatic impairment, dose reduction may be necessary; renal dysfunction has limited effect.

Therapeutic Uses / Clinical Applications

Anti‑amoebic Drugs

• Metronidazole – First‑line therapy for amoebic dysentery, amoebic colitis, liver abscesses, and extra‑intestinal amoebiasis. Common regimens include 500 mg orally thrice daily for 7–10 days, with a 10‑day eradication therapy for abscesses.
• Tinidazole – Alternative to metronidazole for amoebiasis and giardiasis; once‑daily dosing enhances compliance. Typical dosing: 2 g orally once.
• Iodoquinol – Used for amoebic colitis and chronic infection; recommended 500 mg orally twice daily for 8 weeks.
• Paromomycin – Reserved for patients intolerant to metronidazole; administered 25 mg/kg/day in divided doses for 7 days.
• Nitazoxanide – Indicated for giardiasis and cryptosporidiosis; dosing: 500 mg orally twice daily for 5 days.

Anthelmintic Drugs

• Albendazole – Broad spectrum coverage of roundworms, tapeworms, and flukes. Dosage: 400 mg orally once daily for 3 days (intestinal parasites) or 400 mg daily for 7 days (pulmonary or systemic infections).
• Mebendazole – Effective against Ascaris lumbricoides, Trichuris trichiura, and hookworms. Standard regimen: 100 mg orally twice daily for 3 days.
• Ivermectin – First‑line therapy for onchocerciasis, strongyloidiasis, and scabies. Typical dosing: 200 µg/kg orally once.
• Pyrantel Pamoate – Used for pinworm (Enterobius vermicularis) and hookworm infection. Dosage: 11 mg/kg orally once.
• Pyrimethamine & Sulfadiazine – Combination therapy for toxoplasmosis; 25 mg/kg/day of pyrimethamine plus 25 mg/kg/day of sulfadiazine divided into 4 doses.
• Praziquantel – Indicated for schistosomiasis and other trematode infections; dosing: 40 mg/kg orally in a single dose.

Off‑label uses include metronidazole for bacterial vaginosis and certain anaerobic infections, ivermectin for lice, and albendazole for cysticercosis prophylaxis in endemic areas.

Adverse Effects

Anti‑amoebic Drugs

• Metronidazole – Common GI upset, metallic taste, headache, and nausea. Neurotoxicity (paresthesia, ataxia) may occur with cumulative dosing or in patients with renal impairment. Rarely, hypersensitivity reactions and hepatotoxicity have been reported. A black box warning exists for serious neurotoxicity and hepatotoxicity in patients with long‑term use.
• Tinidazole – Similar GI disturbances; rare reports of dermatitis and photosensitivity. Serious hepatotoxicity is uncommon but has been documented.
• Iodoquinol – GI irritation; rare cases of agranulocytosis and hepatotoxicity.
• Paromomycin – Minimal systemic toxicity; ototoxicity and nephrotoxicity are rare due to low absorption.
• Nitazoxanide – GI upset and headache. Anaphylactic reactions are extremely rare.

Anthelmintic Drugs

• Albendazole – Hepatotoxicity (elevated transaminases), bone marrow suppression (rare), headache, and abdominal pain. A black box warning addresses hepatotoxicity and bone marrow suppression during prolonged therapy.
• Mebendazole – Mild GI upset; rare hepatotoxicity reported with high doses.
• Ivermectin – Neurotoxic effects (dizziness, confusion) particularly in patients with GABA‑transfer protein mutations. Rare hypersensitivity reactions and hepatotoxicity.
• Pyrantel Pamoate – GI discomfort; rarely, allergic reactions.
• Pyrimethamine & Sulfadiazine – Hemolytic anemia (especially in G6PD deficiency), bone marrow suppression, and hypersensitivity. Sulfadiazine may provoke photo‑sensitivity.
• Praziquantel – Nausea, vomiting, headache, and dizziness. Rarely, severe allergic reactions.

Monitoring of liver function tests is recommended for patients on albendazole, metronidazole, or pyrimethamine. Complete blood counts should be checked for agents associated with bone marrow suppression.

Drug Interactions

Anti‑amoebic Drugs

• Metronidazole – Inhibits CYP2E1, increasing plasma concentrations of alcohol, disulfiram, and acetaminophen. Concomitant use with warfarin may enhance anticoagulant effects. It also potentiates the neurotoxicity of phenytoin and carbamazepine.
• Tinidazole – Similar interactions as metronidazole; caution with anticoagulants and antiepileptics.
• Iodoquinol – No significant CYP interactions; however, it may increase the risk of hemolysis in G6PD‑deficient patients.
• Paromomycin – Minimal interactions due to low systemic absorption.
• Nitazoxanide – Mild inhibition of CYP3A4; may raise levels of statins and oral contraceptives.

Anthelmintic Drugs

• Albendazole – Strong CYP3A4 inhibitor; increases levels of cyclosporine, oral contraceptives, and anti‑arrhythmic agents. Caution with drugs metabolized by CYP3A4.
• Mebendazole – Mild CYP3A4 inhibition; may affect warfarin and tacrolimus.
• Ivermectin – Inhibits CYP3A4 and P‑glycoprotein; increases plasma concentrations of midazolam, cyclosporine, and statins.
• Pyrantel Pamoate – No significant interactions.
• Pyrimethamine & Sulfadiazine – Sulfadiazine is a CYP2C9 inhibitor; may enhance the effect of warfarin. Pyrimethamine may potentiate the toxicity of antimetabolites.
• Praziquantel – CYP3A4 inhibitor; increases plasma levels of other CYP3A4 substrates.

Patients should be advised to avoid alcohol while on metronidazole or tinidazole due to the risk of disulfiram‑like reactions.

Special Considerations

Pregnancy / Lactation

Metronidazole is classified as category B; however, prolonged use during pregnancy may not be recommended. Alternatives such as tinidazole or paromomycin are preferred. Lactation is generally considered safe, but infant exposure should be minimized due to the drug’s oral excretion.

Albendazole is category C; pregnancy exposure may be associated with teratogenicity in animal studies. Use is discouraged unless benefits outweigh risks. Lactation may expose the infant to the drug via milk; caution is advised.

Ivermectin is category C; human data are limited. Use is avoided in pregnancy and lactation unless essential. Alternatives like albendazole or mebendazole may be considered.

Other anthelmintics (pyrantel, praziquantel) are generally category B; they are considered safe in pregnancy and lactation, though monitoring is recommended.

Pediatrics / Geriatrics

Pediatric dosing often requires weight‑based calculations. For example, albendazole is 400 mg once daily for children > 15 kg. In infants, lower doses and increased frequency may be necessary. Geriatric patients may exhibit altered pharmacokinetics; dose adjustments are seldom required for most anthelmintics but may be considered for drugs with narrow therapeutic indices.

Renal / Hepatic Impairment

Metronidazole and albendazole require dose adjustments in severe hepatic dysfunction due to accumulation of active metabolites. Renal impairment generally has minimal impact on most anti‑amoebic agents; however, metronidazole may accumulate in severe renal failure, necessitating dose reduction.

For anthelmintics, albendazole dosing should be reduced in hepatic insufficiency; mebendazole’s elimination is unaffected by renal disease. Ivermectin may accumulate in hepatic impairment; renal dysfunction has limited effect.

Summary / Key Points

• Anti‑amoebic drugs such as metronidazole and tinidazole act via nitro‑radical production, whereas anthelmintics like albendazole disrupt microtubule dynamics.
• Pharmacokinetic profiles vary widely; absorption enhancers (e.g., fatty meals) can significantly affect drug exposure.
• Hepatotoxicity and bone marrow suppression are prominent concerns for many agents; regular monitoring of liver enzymes and blood counts is advisable.
• Drug interactions, particularly involving CYP3A4 inhibition, are common and may require dose adjustments or alternative therapies.
• Special populations (pregnancy, lactation, renal or hepatic impairment) necessitate careful consideration of drug safety and efficacy; dose modifications or alternative agents should be employed when appropriate.

Comprehensive knowledge of the pharmacological properties of anti‑amoebic and anthelmintic agents enables clinicians to tailor therapy, mitigate adverse effects, and optimize patient outcomes in the management of parasitic infections.

References

1. Chabner BA, Longo DL. Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice. 6th ed. Philadelphia: Wolters Kluwer; 2019.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.